 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C15H20Cl2N2O3 |
| Molar mass | 347.24 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Raclopride is atypical antipsychotic. It acts as a selectiveantagonist onD2dopamine receptors.[1] It has been used in trials studyingParkinson Disease.[2]
Its selectivity to the cerebralD2 receptors is characterized by its respective Ki-values, which are as follows: 1.8, 3.5, 2400 and 18000 nM forD2,D3,D4 andD1 receptors respectively.
It can beradiolabelled withradioisotopes, e.g.3H or11C and used as a tracer forin vitro imaging (autoradiography) as well asin vivo imagingpositron emission tomography (PET). Images obtained by cerebral PET scanning (e.g. PET/CT or PET/MRI) allow the non-invasive assessment of the binding capacity of the cerebralD2 dopaminereceptor, which can be useful for the diagnosis of movement disorders. In particular, cerebral D2 receptor binding as measured by carbon-11-raclopride (11C-raclopride) has shown to reflect disease severity ofHuntington's disease, a genetic disease characterized by selective degeneration of cerebralD2 receptors.[3]
Other studies have investigated the relationship ofD2 receptor binding capacity andpersonality disorders. One study found decreased binding in thedetachmentpersonality trait.[4] Radiolabelled raclopride is also commonly used to determine the efficacy andneurotoxicity ofdopaminergic drugs.
{{cite journal}}: CS1 maint: multiple names: authors list (link) | Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it. |